Key result
Cardioselective beta-blocker use in COPD patients undergoing vascular surgery was associated with lower 30-day (OR 0.37; 95% CI 0.19-0.72) and long-term mortality (HR 0.73; 95% CI 0.60-0.88).
Why the study?
Does cardioselective beta-blocker use reduce 30-day and long-term mortality in patients with COPD undergoing major vascular surgery?
Cohort (n=3,371)
No
Does cardioselective beta-blocker use reduce 30-day and long-term mortality in patients with COPD undergoing major vascular surgery?
Odds Ratio: 0.37 (95% CI 0.19–0.72)
Cardioselective beta-blockers, particularly at intensified doses, are associated with reduced 30-day and long-term mortality in patients with COPD undergoing major vascular surgery.
No takes yet. Share an insight, caveat, or question.
May support selective cardioselective beta-blocker use in COPD vascular surgery patients; leaves open need for RCTs.
Gestel et al. (2008) conducted a cohort in Chronic Obstructive Pulmonary Disease and Atherosclerosis (n=3,371). Cardioselective beta-blockers vs. No cardioselective beta-blockers was evaluated on 30-day mortality (OR 0.37, 95% CI 0.19-0.72). Cardioselective beta-blocker use in COPD patients undergoing vascular surgery was associated with lower 30-day (OR 0.37; 95% CI 0.19-0.72) and long-term mortality (HR 0.73; 95% CI 0.60-0.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: